Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.2K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulatory T cells in pregnancy disorders: a multi-dimensional framework for biomarkers and therapeutic strategies.

Frontiers in immunology·2026
Same author

Stress-adapted cancer-associated fibroblasts as mediators of immunosuppression and therapy resistance.

Cancer letters·2026
Same author

Designing next-generation interleukin immunotherapy: A cytokine-guided framework for precision cancer therapy.

Cytokine & growth factor reviews·2026
Same author

Synergistic senolytic-regenerative therapy significantly extends healthspan and lifespan.

Journal of translational medicine·2026
Same author

The effect of exercise interventions on enhancing psychological resilience: a systematic review and meta-analysis.

BMC psychology·2026
Same author

Integrated gut metagenomic and muscle proteomic analysis reveals the role of dietary fermented extruded brewers' spent grain in enhancing pork quality through the gut-muscle axis.

Journal of animal science and biotechnology·2026

Related Experiment Video

Updated: Dec 4, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.3K

Novel Survivin Peptides Screened With Computer Algorithm Induce Cytotoxic T Lymphocytes With Higher Cytotoxic

Qiuqiang Chen1, Gang Jia2, Xiaolei Zhao3

  • 1Key Laboratory for Translational Medicine, The First Hospital Affiliated to Huzhou University School of Medicine, Huzhou, China.

Frontiers in Molecular Biosciences
|October 26, 2020
PubMed
Summary

Novel decapeptides targeting Survivin (SV) were developed to enhance cancer immunotherapy. Two modified peptides, SV95-6 and SV95-7, demonstrated superior ability to induce cancer-killing immune cells, offering a promising new avenue for treating SV-expressing cancers.

Keywords:
cancer immunotherapycytotoxic T lymphocytepeptidepolymeric nanoparticlesurvivin

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.9K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.1K

Related Experiment Videos

Last Updated: Dec 4, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.3K
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.9K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.1K

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Survivin (SV) is a crucial tumor antigen overexpressed in most cancers but absent in normal tissues, making it a prime target for cancer immunotherapy.
  • Developing effective cancer therapeutics requires identifying novel biomarkers and therapeutic targets, particularly for advanced cancer stages.

Purpose of the Study:

  • To design and validate novel SV decamers capable of inducing SV-specific cytotoxic T lymphocytes (CTLs) with enhanced cytotoxic efficiency against cancer cells.
  • To identify new HLA-A2-restricted CTL epitopes derived from Survivin for potential use in cancer immunotherapy.

Main Methods:

  • Major histocompatibility complex (MHC) peptide binding algorithms were used to predict nine modified SV decamers based on the natural SV95-104 sequence.
  • MHC stability assays determined peptide binding affinity, followed by the generation of SV95-specific CTLs using dendritic cells (DCs) loaded with SV95 peptides via PLGA nanoparticles.
  • IFN-γ ELISpot and CytoTox 96 assays were employed to assess the cytotoxic efficiency of the generated SV95-specific CTLs against target cells.

Main Results:

  • The HLA-A2-restricted mutated SV95 decamers, SV95-6 and SV95-7, exhibited significantly higher binding ability in MHC stability assays compared to the natural SV95-1 peptide.
  • SV95-specific CTLs induced by SV95-6 and SV95-7 peptides demonstrated significantly enhanced cytotoxicity, effectively eliminating target cells, including SV-positive cancer cells.
  • The efficacy of CTLs generated with SV95-6 and SV95-7 was superior to those generated with the natural SV95-1 peptide and TIL2080 cells.

Conclusions:

  • The novel peptides SV95-6 and SV95-7 represent promising HLA-A2-restricted CTL epitopes derived from Survivin.
  • These peptides have the potential to be valuable tools for developing advanced immunotherapies targeting cancers that express Survivin.